טוען...
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...
שמור ב:
| הוצא לאור ב: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352889/ https://ncbi.nlm.nih.gov/pubmed/32586039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21124469 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|